BioSpace News Archive

Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.

A2 Biotherapeutics, Inc., a biotechnology company focused on the treatment of solid tumors, announced that key preclinical data related to its proprietary Tmod™ cell therapy platform have been published in Science Translational Medicine and Journal for ImmunoTherapy of Cancer.

The Infectious Disease Research Institute announced that it has exited receivership and is resuming independent operation as the Access to Advanced Health Institute, to better reflect the organization’s renewed focus and evolving mission to protect and improve lives and health around the world.

Today Redox, the company driving interoperability in healthcare, has announced a partnership with Spire Health, the leading digital healthcare company for respiratory remote patient monitoring (RPM).

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close.

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022 at 9:50 a.m. ET.

First Wave BioPharma, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,498,195 shares of its common stock and five-year warrants to purchase up to an aggregate of 6,498,195 shares of common stock at an exercise price of $1.26 per share, at an effective purchase price of $1.385 per share and accompanying warrant.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 12 newly-hired employees options to purchase an aggregate of 97,000 shares of Akebia’s common stock on February 28, 2022, as inducements material to each such employee’s entering into employment with Akebia.

Acer Therapeutics Inc. (Nasdaq: ACER), today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company’s recent corporate developments.

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announced the closing of its underwritten public offering of $1.2 billion aggregate principal amount of the following notes, each issued at par.